Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Juno Therapeutics Inc. (JUNO) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (55)	3/1/2017 6:26:09 PM
From: Biotech Jim	1 Recommendation Recommended By mopgcw Read Replies (1) \| Respond to of 84

I was hoping that JCAR015 would be terminated, as why waste $$ on an inferior construct/drug. This is the blowout needed for the stock to bottom? I think this is what I have been looking for. I thought picking up shares at $21 and change was wise, and I will continue to buy if they shares fade off of that general level Better constructs, less of the $928M cash at hand that will be wasted. As Barry Bloom (former CEO R&D head) told me a ways back, you have to know when to kill a project, because science is one thing, but commerciality is another much more important kettle of fish. (I think I know fish, or at least fishing). If things go my way, I will quintuple my JUNO position over the next couple of months, probably starting tomorrow. Go hard with the best construct. Wonder if there is good data (ie predictive) on animal model cytokine release syndrome (as I call it). Here is the 8K link: archive.fast-edgar.com (hope it works)